A peptide with anticancer activity
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Product Categories

Fexapotide (trifluoroacetate)

Item No. 40716

Technical Information
Formal Name
L-isoleucyl-L-α-aspartyl-L-glutaminyl-L-glutaminyl-L-valyl-L-leucyl-L-seryl-L-arginyl-L-isoleucyl-L-lysyl-L-leucyl-L-α-glutamyl-L-isoleucyl-L-lysyl-L-arginyl-L-cysteinyl-L-leucine, trifluoroacetate
CAS Number
1609252-56-3
Synonyms
  • NX-1207
Molecular Formula
C90H163N27O25S • 5CF3COOH
Formula Weight
Purity
≥95%
A solid
Peptide Sequence
IDQQVLSRIKLEIKRCL-OH
DMSO: Soluble: ≥10 mg/mlPBS (pH 7.2): Slightly Soluble: 0.1-1 mg/ml
SMILES
O=C(N[C@@H](CC(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CCCCN)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CS)C(N[C@H](C(O)=O)CC(C)C)=O)=O)=O)=O)=O)=O)[C@H](CCCCN)NC([C@H]([C@@H](C)CC)NC([C@H](CCCNC(N)=N)NC([C@H](CO)NC([C@H](CC(C)C)NC([C@H](C(C)C)NC([C@H](CCC(N)=O)NC([C@H](CCC(N)=O)NC([C@H](CC(O)=O)NC([C@@H](N)[C@@H](C)CC)=O)=O)=O)=O)=O)=O)=O)=O)=O.FC(F)(F)C(O)=O.FC(F)(F)C(O)=O.FC(F)(F)C(O)=O.FC(F)(F)C(O)=O.FC(F)(F)C(O)=O
InChi Code
InChI=1S/C90H163N27O25S.5C2HF3O2/c1-15-48(12)68(95)84(137)110-60(41-67(123)124)81(134)105-55(28-31-64(93)119)75(128)104-56(29-32-65(94)120)77(130)115-69(47(10)11)85(138)111-59(39-45(6)7)80(133)113-62(42-118)82(135)103-54(27-23-37-101-90(98)99)76(129)116-70(49(13)16-2)86(139)108-52(25-19-21-35-92)73(126)109-58(38-44(4)5)79(132)106-57(30-33-66(121)122)78(131)117-71(50(14)17-3)87(140)107-51(24-18-20-34-91)72(125)102-53(26-22-36-100-89(96)97)74(127)114-63(43-143)83(136)112-61(88(141)142)40-46(8)9;5*3-2(4,5)1(6)7/h44-63,68-71,118,143H,15-43,91-92,95H2,1-14H3,(H2,93,119)(H2,94,120)(H,102,125)(H,103,135)(H,104,128)(H,105,134)(H,106,132)(H,107,140)(H,108,139)(H,109,126)(H,110,137)(H,111,138)(H,112,136)(H,113,133)(H,114,127)(H,115,130)(H,116,129)(H,117,131)(H,121,122)(H,123,124)(H,141,142)(H4,96,97,100)(H4,98,99,101);5*(H,6,7)/t48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,68-,69-,70-,71-;;;;;/m0...../s1
InChi Key
IBMWAUVJJROIMB-IWEBAUSJSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Add

    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Fexapotide (trifluoroacetate) is a peptide.1 It induces apoptosis in LNCaP prostate cancer cells when used at a concentration of 2.5 mg/ml. Intraprostatic administration of fexapotide triflutate (0.6 mg/animal per week) reduces the numbers of prostate glandular epithelial cells without affecting other cell types and decreases prostate volume in rats.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Averback, P., Gohal, R., Fuska, M., et alFexapotide triflutate induces selective prostate glandular pharmaco-ablation in the rat. Res. Rep. Urol. 11, 343-350 (2019).